Are They Side Effects? Extraintestinal Symptoms Reported During Clinical Trials of Irritable Bowel Syndrome May Be More Severe at Baseline.
Adverse Events
Clinical Trials
Extraintestinal Symptoms
Irritable Bowel Syndrome
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
20
10
2021
revised:
07
03
2022
accepted:
12
03
2022
pubmed:
28
3
2022
medline:
29
11
2022
entrez:
27
3
2022
Statut:
ppublish
Résumé
Many of the reported adverse events in clinical trials of irritable bowel syndrome are extraintestinal symptoms, which typically are assessed by open-ended questions during the trial and not at baseline. This may lead to misattribution of some pre-existing symptoms as side effects to the treatment. The current study analyzed data from a 6-week clinical trial of irritable bowel syndrome. Participants were randomized to receive double-blind peppermint oil, double-blind placebo, or treatment as usual. Extraintestinal symptoms were assessed at baseline and at the end of the study. This analysis included 173 participants (30 received double-blind peppermint oil, 72 received treatment as usual, and 71 received double-blind placebo). At baseline, each group reported approximately 5 extraintestinal symptoms per participant. The number of symptoms per participant decreased to an average of 3 by the end-of-study visit, and this change was statistically significant in all groups (P < .001 for each group). When evaluating individual extraintestinal symptoms, the majority of participants did not report new/worse symptoms. In fact, between the baseline assessment and the final assessment, the average symptom severity decreased significantly in all 3 groups (P < .001). Our study suggests that participants with irritable bowel syndrome often experience extraintestinal symptoms at baseline and that these symptoms generally improve in severity over the course of a clinical trial, regardless of the treatment arm. Systematic assessment of extraintestinal symptoms at the beginning of a clinical trial is necessary to determine more definitively whether these symptoms may be considered an adverse event attributable to a study medication.
Sections du résumé
BACKGROUND & AIMS
Many of the reported adverse events in clinical trials of irritable bowel syndrome are extraintestinal symptoms, which typically are assessed by open-ended questions during the trial and not at baseline. This may lead to misattribution of some pre-existing symptoms as side effects to the treatment.
METHODS
The current study analyzed data from a 6-week clinical trial of irritable bowel syndrome. Participants were randomized to receive double-blind peppermint oil, double-blind placebo, or treatment as usual. Extraintestinal symptoms were assessed at baseline and at the end of the study.
RESULTS
This analysis included 173 participants (30 received double-blind peppermint oil, 72 received treatment as usual, and 71 received double-blind placebo). At baseline, each group reported approximately 5 extraintestinal symptoms per participant. The number of symptoms per participant decreased to an average of 3 by the end-of-study visit, and this change was statistically significant in all groups (P < .001 for each group). When evaluating individual extraintestinal symptoms, the majority of participants did not report new/worse symptoms. In fact, between the baseline assessment and the final assessment, the average symptom severity decreased significantly in all 3 groups (P < .001).
CONCLUSIONS
Our study suggests that participants with irritable bowel syndrome often experience extraintestinal symptoms at baseline and that these symptoms generally improve in severity over the course of a clinical trial, regardless of the treatment arm. Systematic assessment of extraintestinal symptoms at the beginning of a clinical trial is necessary to determine more definitively whether these symptoms may be considered an adverse event attributable to a study medication.
Identifiants
pubmed: 35339669
pii: S1542-3565(22)00293-2
doi: 10.1016/j.cgh.2022.03.018
pmc: PMC9500110
mid: NIHMS1791914
pii:
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2888-2894.e1Subventions
Organisme : NCCIH NIH HHS
ID : R01 AT008573
Pays : United States
Informations de copyright
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Gastroenterology. 2021 Jan;160(1):99-114.e3
pubmed: 32294476
J Clin Epidemiol. 2014 Mar;67(3):267-77
pubmed: 24275499
Int J Epidemiol. 2005 Feb;34(1):215-20
pubmed: 15333621
J Psychosom Res. 2008 Jun;64(6):573-82
pubmed: 18501257
Am J Gastroenterol. 2021 Nov 1;116(11):2279-2285
pubmed: 34319275
Arch Intern Med. 2009 Oct 26;169(19):1737-9
pubmed: 19858427
J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1137-43
pubmed: 18070012
Pain. 2021 Sep 1;162(9):2428-2435
pubmed: 33605656
Aliment Pharmacol Ther. 1997 Apr;11(2):395-402
pubmed: 9146781
J Affect Disord. 2009 Apr;114(1-3):163-73
pubmed: 18752852
JAMA. 2002 Feb 6;287(5):622-7
pubmed: 11829702
Clin Gastroenterol Hepatol. 2009 Apr;7(4):446-51
pubmed: 19167522
Am J Psychiatry. 1967 Jan;123(7):875-8
pubmed: 5334522
N Engl J Med. 1968 Sep 26;279(13):678-9
pubmed: 5670907
Drug Saf. 2009;32(11):1041-56
pubmed: 19810776
Ann Intern Med. 1964 Feb;60:255-65
pubmed: 14117698
Trials. 2017 May 25;18(1):234
pubmed: 28545508
Arch Intern Med. 2006 Jan 23;166(2):155-60
pubmed: 16432082
Exp Clin Psychopharmacol. 2018 Jun;26(3):320-326
pubmed: 29863388
Behav Cogn Psychother. 2019 Jul;47(4):431-445
pubmed: 30400997
Gastroenterology. 2016 Feb 18;:
pubmed: 27144627